Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/070385external-prioritypatent/WO2012066095A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of TN2013000194A1publicationCriticalpatent/TN2013000194A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4- methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4dihydro-2H- isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, (I).
TNP2013000194A2011-11-172013-05-03Crystalline form of an inhibitor of mdm 2/4 and p53 interaction
TN2013000194A1
(en)
Smoking article, with a filter unit, and a removable protective cover, attached to the article by means of an adhesive; method of providing a smoking article with a removable cover.